[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341040-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341040-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinically-observed-foxa1-mutations-upregulate-sema3c-through-transcriptional-derepression-in-prostate-cancer","Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer","","FOXA1 is a pioneer transcription factor frequently mutated in metastatic castration-resistant prostate cancer, yet the mechanisms behind its oncogenic effects remain unclear. This study characterizes FOXA1 alterations and identifies semaphorin 3C (SEMA3C) as a key FOXA1-regulated target. FOXA1 variants increase SEMA3C levels in prostate cancer specimens and in vitro. FOXA1 suppresses SEMA3C via intronic cis elements, and FOXA1 forkhead domain mutations reduce this inhibition. The findings link FOXA1-driven SEMA3C expression to cancer progression and treatment resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinically-observed-foxa1-mutations-upregulate-sema3c-through-transcriptional-derepression-in-prostate-cancer/341040/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinically-observed-foxa1-mutations-upregulate-sema3c-through-transcriptional-derepression-in-prostate-cancer/341040.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do FOXA1 mutations play in metastatic castration-resistant prostate cancer (mCRPC)?","Question",{"text":63,"@type":64},"FOXA1 mutations are commonly found in mCRPC, but how FOXA1 variants drive oncogenic effects was unclear. This study focuses on how FOXA1 variants regulate downstream signaling relevant to tumor progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does FOXA1 alter SEMA3C expression?",{"text":68,"@type":64},"FOXA1 alterations lead to elevated SEMA3C levels in prostate cancer specimens and in vitro. FOXA1 negatively regulates SEMA3C via intronic cis elements.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are FOXA1 forkhead domain mutations important to SEMA3C regulation?",{"text":72,"@type":64},"Mutations in the FOXA1 forkhead domain attenuate FOXA1’s inhibitory function in reporter assays, likely by disrupting FOXA1 DNA binding. This supports a mechanism connecting FOXA1 variant biology to increased SEMA3C expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341040,1790155828,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nClinically‑observed FOXA1 mutations upregulateSEMA3C through transcriptional derepression in prostate cancer  \nKevin J. Tam1, Liangliang Liu1, Michael Hsing1, Kush Dalal1, Daksh Thaper1,2, Brian McConeghy1, Parvin Yenki1,2, Satyam Bhasin1,2, James W. Peacock1,2, Yuzhuo Wang1,2,3, Artem Cherkasov1,2, Paul S. Rennie1,2, Martin E. Gleave 1,2 & Christopher J. Ong1,2*  \nFOXA1 is a pioneer transcription factor that is frequently mutated in prostate, breast, bladder, and salivary gland malignancies. Indeed, metastatic castration‑resistant prostate cancer (mCRPC) commonly harbour FOXA1 mutations with a prevalence of 35% . However, despite the frequent recurrence of FOXA1 mutations in prostate cancer, the mechanisms by which FOXA1 variants drive its oncogenic effects are still unclear. Semaphorin 3C (SEMA3C) is a secreted autocrine growth factor that drives growth and treatment resistance of prostate and other cancers and is known tobe regulated by both AR and FOXA1 . In the present study, we characterize FOXA1 alterations with respect to its regulation of SEMA3C. Our findings reveal that FOXA1 alterations lead to elevated levels ofSEMA3C both in prostate cancer specimens and in vitro. We further show that FOXA1 negatively regulates SEMA3Cvia intronic cis elements, and that mutations in FOXA1 forkhead domain attenuate its inhibitory function in reporter assays, presumably by disrupting DNA binding of FOXA1 . Our findings underscore the key role of FOXA1 in prostate cancer progression and treatment resistance by regulating SEMA3C expression and suggest that SEMA3C may be a driver of growth and tumor vulnerability of mCRPC harboring FOXA1 alterations.  \nFOXA1, a member of the forkhead box family of transcription factors, acts as a pioneer factor that binds to and de-compacts condensed chromatin to facilitate access of other transcription factors and transcriptional machinery to initiate the transcriptional cascade1–6. FOXA1 is well-documented to influence AR activity and can dramatically affect its cistrome7–10 leading to the up-or down-regulation of a large number of genes. However, the relationship between the AR and FOXA1 is complex. In prostate cancer, FOXA1 is known to have AR-dependent and AR-independent activities10, 11; moreover, in those that are AR-dependent, FOXA1 can exert both positive and negative effects on expression ofAR-regulated genes11–13. The nuances of FOXA1-AR interplay are likely dependent on biological context as well as proximity and arrangement of genomic FOXA1 motifs in relation to AR motifs.  \nLandmark genomic studies have revealed that FOXA1 is among the most frequently-mutated genes in prostate cancer patients9, 14–17. These mutations have been documented in multiple independent clinical cohorts and associated with poor prognosis suggesting that FOXA1 lesions may be a biomarker with potential diagnostic or prognostic significance. Recent coinciding reports have begun to unravel the clinical importance of FOXA1 mutations in PCa18, 19. Adams et al. identified two mutation hotspots in FOXA1 and demonstrated that FOXA1 variants trigger phenotypic changes by promoting growth and inducing epithelial-to-mesenchymal transition (EMT). Parolia et al. define three unique classes of FOXA1 variants that behave differently with respect to its effects on FOXA1 transcriptional activity and cell growth. However, molecular mechanisms by which FOXA1 variants mediate these tumor-promoting activities remain poorly understood.  \nTo address this gap, we identified semaphorin 3C (SEMA3C) as a candidate FOXA1 target gene that might mediate the pro-oncogenic effects such as increased proliferation and EMT linked with FOXA1 variants in  \n1Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada. 2Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 3Department of Experimental Therapeutics, BC Cancer A","cbCaid1wtgdcoAJQ","https://ap.wps.com/l/cbCaid1wtgdcoAJQ","pdf",4823281,12,"English","# Introduction\n## FOXA1 mutations and prostate cancer context\n## AR–FOXA1 interplay and genomic regulation\n# Target identification and rationale\n## SEMA3C as a candidate FOXA1 target\n## Links to growth, resistance, EMT, and stemness\n# Study approach and aims\n## Clinically observed FOXA1 mutations and SEMA3C expression","[{\"question\":\"What role do FOXA1 mutations play in metastatic castration-resistant prostate cancer (mCRPC)?\",\"answer\":\"FOXA1 mutations are commonly found in mCRPC, but how FOXA1 variants drive oncogenic effects was unclear. This study focuses on how FOXA1 variants regulate downstream signaling relevant to tumor progression.\"},{\"question\":\"How does FOXA1 alter SEMA3C expression?\",\"answer\":\"FOXA1 alterations lead to elevated SEMA3C levels in prostate cancer specimens and in vitro. FOXA1 negatively regulates SEMA3C via intronic cis elements.\"},{\"question\":\"Why are FOXA1 forkhead domain mutations important to SEMA3C regulation?\",\"answer\":\"Mutations in the FOXA1 forkhead domain attenuate FOXA1’s inhibitory function in reporter assays, likely by disrupting FOXA1 DNA binding. This supports a mechanism connecting FOXA1 variant biology to increased SEMA3C expression.\"}]","Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer | PDF",1790040073,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8394e453380e8851302fb5d8238f741.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f07510b092f8c297824aba4fbe635a2.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce174fb9c1255b3defae21069950be1d.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af2c7608791ce7ef41116f8ab5d2f38e.webp",980,1287]